Results of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which compared dapagliflozin (10 mg once daily) to placebo, found that dapagliflozin was associated with a 44% reduction in a composite of adverse kidney outcomes and a 29% reduction in death from cardiovascular causes or hospitalization for heart failure
Choices in Event of Insurance Denial Patients denied coverage for GLP-1 drugs by their insurance carriers have three choices
237 Although glutamine is a nonessential amino acid, PDAC cells depend on exogenous glutamine metabolism for their anabolic processes, including serving as a carbon source for lipid biosynthesis and a nitrogen source for nonessential amino acid and nucleotide biosynthesis
NSF What Food & Beverage Brands Should Do Now If your business manufactures, imports, or packages food products for the Canadian market, consider these actions: Review product portfolios against the new nutrient thresholds to identify items requiring a warning symbol
Pharmacological properties: Semaglutide is an insulin-like peptide-1 receptor agonist whose main pharmacological action is to mimic the action of GLP-1 produced in the body
